Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Clinigen an ‘undervalued opportunity’ – broker

N+1 Singer, which starts covering the stock with a ‘buy’ rating, points out that the drug development group’s services revenues are lumpy, which appears to have put investors off buying the shares this year.

Shares in Clinigen (LON:CLIN) are trading too low, according to broker N+1 Singer.

Analyst Elizabeth Klein, who starts covering the stock with a ‘buy’ rating, points out that the drug development group’s services revenues are lumpy, which appears to have put investors off buying the shares this year.

However, she thinks the improving margins should start tempting investors back to the company, which is still worth more than £300mln after 2013’s strong share price run.

Klein says that with gross margins of 70-80%, the specialty pharma division “should help to grow Clinigen’s profits faster than revenues”.

She notes that this part of the business is still early in the growth phase, with four drugs and with plans to acquire around six more over the next three-five years.

Her target price for the stock is 439p, which is some 70p higher than the current price of 374p.

“The model is still evolving for Clinigen but we expect the highly experienced management team to manage the uneven Services revenue streams over the next few years, and at the same time to acquire new drugs for its rapidly growing Specialty Pharmaceuticals division,” says Klein.

She adds: “We believe the 3m underperformance of the shares may have been due to the expected risk associated with the lumpy Services divisions and the founder’s overhang: 6.4% of the c31% stake was recently sold and performance subsequently improved. 

“Even though there remains significant risk with the timing of Services revenues, the improving margins and the upside to the valuation moderates this.”


View full CLIN profile View Profile

Clinigen Group PLC Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
scientist in lab
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use